Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

Catalytic activity is not required for secreted PCSK9 to reduce low density lipoprotein receptors in HepG2 cells.

The Journal of biological chemistry - 20 Jul 2007

McNutt Markey C, Lagace Thomas A, Horton Jay D

Abstract excerpt

Proprotein convertase subtilisin/kexin type 9 (PCSK9), a member of the proteinase K subfamily of subtilases, promotes internalization and degradation of low density lipoprotein receptors (LDLRs) after binding the receptor on the surface of hepatocytes. PCSK9 has autocatalytic activity that releas...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Catalysis
Share to Epitopes
Share to Genetic Vectors

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Share to Molecular Chaperones

Share to Proprotein Convertase 9

Share to Proprotein Convertases

Share to Receptors, LDL

Share to Serine Endopeptidases

Source

Open in PubMed Open full text

Identifiers

PMID: 17537735
DOI: 10.1074/jbc.C700095200
PMCID: PMC13276728

Genes

PCSK9
LDLR

Variants

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 2 Sept 2026. Prepared record publication-17537735-2026-09-02.2. Manifest publication-graph-cohort-2026-09-02.2.

Source receipt: PubMed via Helena Literature Corpus, retrieved 2 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

Catalytic activity is not required for secreted PCSK9 to reduce low density lipoprotein receptors in HepG2 cells.PMID 17537735Read ↗

Secreted PCSK9 promotes LDL receptor degradation independently of proteolytic activity.Semantic proximity Read ↗

Secreted PCSK9 decreases the number of LDL receptors in hepatocytes and in livers of parabiotic mice.Semantic proximity Read ↗

The biology of PCSK9 from the endoplasmic reticulum to lysosomes: new and emerging therapeutics to control low-density lipoprotein cholesterol.Semantic proximity Read ↗

PCSK9: a key modulator of cardiovascular health.Semantic proximity Read ↗

Novel loss-of-function PCSK9 variant is associated with low plasma LDL cholesterol in a French-Canadian family and with impaired processing and secretion in cell culture.Semantic proximity Read ↗

Internalized PCSK9 dissociates from recycling LDL receptors in PCSK9-resistant SV-589 fibroblasts.Semantic proximity Read ↗

PCSK9 prosegment chimera as novel inhibitors of LDLR degradation.Semantic proximity Read ↗

Roles of the low density lipoprotein receptor and related receptors in inhibition of lipoprotein(a) internalization by proprotein convertase subtilisin/kexin type 9.Semantic proximity Read ↗

Degradation of LDLR protein mediated by 'gain of function' PCSK9 mutants in normal and ARH cells.Semantic proximity Read ↗

The cellular trafficking of the secretory proprotein convertase PCSK9 and its dependence on the LDLR.Semantic proximity Read ↗

A novel splicing variant of proprotein convertase subtilisin/kexin type 9.Semantic proximity Read ↗

Antagonism of secreted PCSK9 increases low density lipoprotein receptor expression in HepG2 cells.Semantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.